Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Disease Reports
castleman disease
MeSH D005871 - castleman disease
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D008232:
Lymphoproliferative disorders
2 Companies
2 Drugs
$
Success rate
D005871:
Castleman disease
1 Company
1 Drug
$
Success rate
Events Timeline
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
Recordati
Siltuximab
Sylvant
2014-04-23
Clinical Trials
Historical Success Rate
Phase 1
18
%
2/11
Phase 2
20
%
1/5
Phase 3
100
%
1/1
Approved:
1
Overall Success rate:
4%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Recordati
Siltuximab
,
Doconexent
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use